TY - JOUR T1 - Diffuse correlation spectroscopy used to monitor cerebral blood flow during adult hypothermic circulatory arrests JF - medRxiv DO - 10.1101/2020.05.14.20098509 SP - 2020.05.14.20098509 AU - Alexander I. Zavriyev AU - Kutlu Kaya AU - Parisa Farzam AU - Parya Y. Farzam AU - John Sunwoo AU - Felipe Orihuela-Espina AU - Arminder S. Jassar AU - Duke E. Cameron AU - Thoralf M. Sundt AU - Serguei Melnitchouk AU - Stefan A. Carp AU - Maria Angela Franceschini AU - Jason Z. Qu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/29/2020.05.14.20098509.abstract N2 - Real-time noninvasive monitoring of cerebral blood flow during surgery could improve the morbidity and mortality rates associated with hypothermic circulatory arrests (HCA) in adult cardiac patients. In this study, we used a combined frequency domain near-infrared spectroscopy (FDNIRS) and diffuse correlation spectroscopy (DCS) system to measure cerebral oxygen saturation (SO2) and an index of blood flow (CBFi) in 12 adults going under cardiac surgery with HCA. Our measurements revealed that a negligible amount of blood is delivered to the brain during HCA with retrograde cerebral perfusion (RCP), indistinguishable from HCA-only cases (CBFi drops of 91% ± 3% and 96% ± 2%, respectively) and that CBFi drops for both are significantly higher than drops during HCA with antegrade cerebral perfusion (ACP) (p = 0.003). We conclude that FDNIRS-DCS can be a powerful tool to optimize cerebral perfusion, and that RCP needs to be further examined to confirm its efficacy, or lack thereof.Competing Interest StatementMAF has a financial interest in 149 Medical, Inc., a company developing DCS technology for assessing and monitoring cerebral blood flow in newborn infants, and in Dynometrics, Inc., a company that makes devices that use NIRS technology for athletes to evaluate muscle performance. MAFs interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.Funding StatementThis work is supported by NIH R01GM116177 and R01HD091067 (MAF), R01NS100750 (SC) and CONACYT 2018-000007-01EXTV (FOE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham (f.k.a Partners Healthcare) Human Research Committee (IRB #2016P001944)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred in the manuscript is available upon request by contacting the corresponding author. ER -